These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 37776485)

  • 1. Clinical Pharmacokinetics of Ponesimod, a Selective S1P1 Receptor Modulator, in the Treatment of Multiple Sclerosis.
    Kruger TM; Valenzuela B; Thompson CD; Ouwerkerk-Mahadevan S; Ruixo JJP
    Clin Pharmacokinet; 2023 Nov; 62(11):1533-1550. PubMed ID: 37776485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial.
    Kappos L; Fox RJ; Burcklen M; Freedman MS; Havrdová EK; Hennessy B; Hohlfeld R; Lublin F; Montalban X; Pozzilli C; Scherz T; D'Ambrosio D; Linscheid P; Vaclavkova A; Pirozek-Lawniczek M; Kracker H; Sprenger T
    JAMA Neurol; 2021 May; 78(5):558-567. PubMed ID: 33779698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ponesimod: An Oral Second-Generation Selective Sphingosine 1-Phosphate Receptor Modulator for the Treatment of Multiple Sclerosis.
    Alnaif A; Oiler I; D'Souza MS
    Ann Pharmacother; 2023 Aug; 57(8):956-965. PubMed ID: 36514282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ponesimod, a selective sphingosine 1-phosphate (S1P
    Dash RP; Rais R; Srinivas NR
    Xenobiotica; 2018 May; 48(5):442-451. PubMed ID: 28489480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacology of ponesimod, a selective S1P₁ receptor modulator, after uptitration to supratherapeutic doses in healthy subjects.
    Hoch M; D'Ambrosio D; Wilbraham D; Brossard P; Dingemanse J
    Eur J Pharm Sci; 2014 Oct; 63():147-53. PubMed ID: 25046167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study.
    Brossard P; Derendorf H; Xu J; Maatouk H; Halabi A; Dingemanse J
    Br J Clin Pharmacol; 2013 Dec; 76(6):888-96. PubMed ID: 23594176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ponesimod, an S1P1 receptor modulator: favorable impact of dose up-titration.
    Brossard P; Scherz M; Halabi A; Maatouk H; Krause A; Dingemanse J
    J Clin Pharmacol; 2014 Feb; 54(2):179-88. PubMed ID: 24408162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial.
    Olsson T; Boster A; Fernández Ó; Freedman MS; Pozzilli C; Bach D; Berkani O; Mueller MS; Sidorenko T; Radue EW; Melanson M
    J Neurol Neurosurg Psychiatry; 2014 Nov; 85(11):1198-208. PubMed ID: 24659797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ponesimod to treat multiple sclerosis.
    Ianniello A; Pozzilli C
    Drugs Today (Barc); 2021 Dec; 57(12):745-758. PubMed ID: 34909803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Efficacy of Relapsing Multiple Sclerosis Therapies: Model-Based Meta-Analyses for Confirmed Disability Accumulation and Annualized Relapse Rate.
    Hennessy B; Zierhut ML; Kracker H; Keenan A; Sidorenko T
    Mult Scler Relat Disord; 2022 Aug; 64():103908. PubMed ID: 35803162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of ponesimod and its primary metabolites in healthy and organ-impaired subjects.
    Lott D; Krause A; Dingemanse J; Lehr T
    Eur J Pharm Sci; 2016 Jun; 89():83-93. PubMed ID: 27108115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ponesimod in the Treatment of Relapsing Forms of Multiple Sclerosis: An Update on the Emerging Clinical Data.
    Ruggieri S; Quartuccio ME; Prosperini L
    Degener Neurol Neuromuscul Dis; 2022; 12():61-73. PubMed ID: 35356493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Demographics, Organ Impairment, Disease, Formulation, and Food on the Pharmacokinetics of the Selective S1P
    Lott D; Lehr T; Dingemanse J; Krause A
    Clin Pharmacokinet; 2017 Apr; 56(4):395-408. PubMed ID: 27638335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Desensitization by progressive up-titration prevents first-dose effects on the heart: guinea pig study with ponesimod, a selective S1P1 receptor modulator.
    Rey M; Hess P; Clozel M; Delahaye S; Gatfield J; Nayler O; Steiner B
    PLoS One; 2013; 8(9):e74285. PubMed ID: 24069292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term Treatment With Ponesimod in Relapsing-Remitting Multiple Sclerosis: Results From Randomized Phase 2b Core and Extension Studies.
    Freedman MS; Pozzilli C; Havrdova EK; Lemle A; Burcklen M; Larbalestier A; Hennessy B; Sidorenko T; Vaclavkova A; Olsson T;
    Neurology; 2022 Aug; 99(8):e762-e774. PubMed ID: 35667837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases.
    D'Ambrosio D; Freedman MS; Prinz J
    Ther Adv Chronic Dis; 2016 Jan; 7(1):18-33. PubMed ID: 26770667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sphingosine-1-phosphate (S1P) displays sustained S1P1 receptor agonism and signaling through S1P lyase-dependent receptor recycling.
    Gatfield J; Monnier L; Studer R; Bolli MH; Steiner B; Nayler O
    Cell Signal; 2014 Jul; 26(7):1576-88. PubMed ID: 24704119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ponesimod: First Approval.
    Markham A
    Drugs; 2021 Jun; 81(8):957-962. PubMed ID: 33939119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An exposure-response analysis of ponesimod clinical efficacy in a randomized phase III study in patients with relapsing multiple sclerosis.
    Valenzuela B; Olsson Gisleskog P; Poggesi I; Sidorenko T; Burcklen M; Kracker H; Pérez-Ruixo JJ
    CPT Pharmacometrics Syst Pharmacol; 2022 Oct; 11(10):1294-1304. PubMed ID: 36047474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of ponesimod, a selective S1P1 receptor modulator, on the pharmacokinetics of a hormonal combination contraceptive.
    Reyes M; Brossard P; Chassard D; Hoch M; Dingemanse J
    Eur J Clin Pharmacol; 2014 Mar; 70(3):287-93. PubMed ID: 24362488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.